J9349
HCPCSInj., tafasitamab-cxix
Official HCPCS Level II long descriptor
Injection, tafasitamab-cxix, 2 mg
HCPCS Level II code J9349 is maintained by CMS and is active in the current quarterly release.
Short descriptor
Inj., tafasitamab-cxix
Added to HCPCS: 2021-04-01
Nearby codes in J9
- J9332Inj efgartigimod 2mg
- J9333Inj rozanolixizum-noli 1 mg
- J9334Inj efgart-alfa 2mg hya-qvfc
- J9341Inj thiotepa (tepylute) 1 mg
- J9342Inj thiotepa nos 1 mg
- J9345Inj, retifanlimab-dlwr, 1 mg
- J9347Inj, tremelimumab-actl, 1 mg
- J9348Inj. naxitamab-gqgk, 1 mg
- J9350Inj mosunetuzumab-axgb, 1 mg
- J9351Topotecan injection
- J9352Injection trabectedin 0.1mg
- J9353Inj. margetuximab-cmkb, 5 mg
- J9354Inj, ado-trastuzumab emt 1mg
- J9355Inj trastuzumab excl biosimi
- J9356Inj. herceptin hylecta, 10mg
- J9357Valrubicin injection
Where this code sits
Krasyn AI Coder
Get code suggestions automatically as you type notes. Free for 50 analyses.
Install for Chrome — freeSource
HCPCS Level II July 2026 quarterly update. Centers for Medicare & Medicaid Services (CMS), “July 2026 Alpha-Numeric HCPCS File” (HCPC2026_JUL_ANWEB_06172026.txt). Download the original file from cms.gov. Public domain (US Government work). Descriptors, billable flags and instructional notes on this page are reproduced from that file without modification. Krasyn adds no clinical guidance.